Pulmatrix (PULM)
(Delayed Data from NSDQ)
$1.97 USD
+0.07 (3.68%)
Updated Jun 7, 2024 03:57 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Pulmatrix, Inc. [PULM]
Reports for Purchase
Showing records 21 - 40 ( 44 total )
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Pulmazole Incremental Phase 2 Progress Paves Way to Data Expected 2H20; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Pulmazole Inhaled iSPERSE Progress Continues, Phase 2 Data Expected 3Q20; Reit Buy and Lowering PT to $10.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Pulmazole Phase 2 Trial on Deck This Quarter, Continued Program Progress; Reit Buy and $22 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Pulmazole Definitive Agreement a Positive Push for iSPERSE Development; PT Change Post Reverse Split
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Awaiting Initiation of Phase 2 POC Study Expected in December 2018; Reit Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Pulmazole Safety and PK Profile: So Far, So Good
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Efficient and Timely Execution Is Important During Early Stage Development; Lowering PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Delivering Therapy Deep Into the Airways; Initiating With Buy Rating and a $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Company Announces Registered Direct Offering
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: GRISEWOOD S